BioPharma Asia Convention 2017 Agenda

Create your personal agenda –check the favourite icon

09:00
Conference pass

Option1: Biotech Bootcamp Part 1

Pre-conference activities
Financing a cure: Getting your business plan and pitch book right, for successful fundraising.
 
In part 1, we explore how to increase your chances of fundraising success, including:
 
  • Plan for success: What makes a strong business plan?
  • Developing your story
  • Maximising your social media presence
  • Protecting your IP
  • Making yourself stand out from the crowd: How can you position your biotech as an innovator?
When do you build a board?
09:01
Conference pass

Option 2: Manufacturing Technical Symposium

Pre-conference activities
This workshop focuses on protein aggregation & characterization methods in downstream purification,, with issues including:
 
  • Understanding protein aggregation mechanisms
  • Identifying the key stages in protein characterization
  • Exploring available downstream & purification techniques and how they impact output and efficiency
09:02
Conference pass

Option 3: Experimental Therapeutics Center, A*STAR

Pre-conference activities
Witness drug discovery capabilities in Asia by joining us at a site tour to Experimental Therapeutics Center (ETC), a member of Agency of Science, Technology & Research (A*STAR). From assay development, high throughput screening, medicinal chemistry and ADME/toxicology, scientists from ETC show you how Singapore translate early stage discoveries towards proof-of-concept and into diagnostic and research tools.
09:10
Conference pass

Is orphan drug regulatory access too complicated to harmonize? ASEAN’s Pharmaceutical Product Working Group’s perspective

Orphan drug congress
  • Recent updates on facilitating economic integration initiatives for pharmaceutical products
  • The Working Group’s perspective on providing orphan drug access to the ASEAN
  • Barriers to entry and what various stakeholders can do to help
09:30
Conference pass

If it’s good for them, it’s good for us: reciprocal approval of orphan drugs

Orphan drug congress
  • Automatic approval of orphan drugs approved by US FDA, EMA and other reputable country regulations to fast-track access
  • Are there Asian countries that are already adopting this?
  • Consequences of not doing a localized clinical trial
09:50
Conference pass

Cheaper alternatives: orphan drug biosimilars

Orphan drug congress
  • Asia’s guidelines to biosimilar drug development: can the same strategies on harmonization and reciprocity be applied?
  • Does Asia have a biosimilar to Zavesca for Gaucher, and is it ready with Increlex for growth failure which will go off-patent in 2017?
  • Preparing for Naglazyme and Soliris off-patent in 2019 – which biosimilar company is doing what?
10:10
Conference pass

Specialty pharma wholesalers and distributors: consolidating rare disease patients from across Asia to meet pharma ROI

Orphan drug congress

•    Investing $500,000 in inventory for a single patient, who has a disease you've probably never heard of
•    Integrating the delivery of specialized pharmacy services with comprehensive, patient-centered health management and patient advocacy
•    Coordinating patients, physicians, nurses, families, manufacturers, patient advocacy groups, and payers to provide the best care and the best quality possible

11:00
Conference pass

Establishing a standard of care

Orphan drug congress
  • Provide a practical and useful model of the standard of care for transparency
  • Streamlining approval processes to increase certainty and clarity
  • If not for a specific rare disease, is it possible to have an evolving standard of care for rare or undiagnosed disease?
11:20
Conference pass

Articulating the value of high-priced orphan drugs but highly specialized technologies

Orphan drug congress
  • Putting patients and care-givers at the heart of the value demonstration equation in orphan drugs
  • Proving to be the only available treatment for a life-threatening disease
  • Re-assessing HTA and standard thresholds for the amount of money per QALY gained
11:40
Conference pass

Pricing & Reimbursement and its real non-impact on government budgets

Orphan drug congress
  • How (orphan) drugs are priced: factoring in product development costs, health benefits and value, patient populations and sustainable business
  • Comparing the cumulative cost for an orphan drug vs. the cost of a blockbuster drug to a government’s health budget
  • Helping physicians and local authorities build sustainable health care systems that can pay for treatment 
  • Offering free drug programs while sustainable systems are being built
13:10
Conference pass

Pricing orphan drugs by cost calculation in Japan

Orphan drug congress
  • Orphan drug designation for drugs, devices and vaccines
  • Using a similar product efficacy comparison method to match the proposed price with the standard of care therapy
  • Adoption of a ‘cost-effectiveness-focused’ HTA in order to reprice a number of existing drugs by 2018
13:30
Conference pass

Rare Diseases Act of the Philippines: an emerging market’s perspective

Orphan drug congress
  • No-fail patient group power and campaigning for 500,000 signature to pass a senate bill on rare disease and orphan drugs
  • Ten key provisions of RA 10747
  • Report and updates on the Technical Working Group for the implementation of the law
13:50
Conference pass

Taiwan’s National Bureau of Health’s commitment to providing all necessary care to rare disease patients

Orphan drug congress
  • PSOD in the Philippines, it’s TFRD in Taiwan: the makings of Taiwan’s Rare Disease and Orphan Drug Act
  • Novel provisions: a logistics centre for emergency orphan drug supply and sponsored diagnosis, ‘40-40-20’
  • Establishing a nationwide expanded newborn screening program
14:00
Conference pass

Option 1: Biotech Bootcamp Part 2

Pre-conference activities
Primer in successful partnership management: Licensing, partnerships and strategic alliance management
 
In part 2, we talk partnerships and growth strategy:
 
  • How to value your biotech start-up
  • What should you be looking for in your partners and how can you make your business more attractive to them?
  • What makes a successful partnership?
  • How do you meet your buy-side customers
  • Getting your pitching strategy right
14:00
Conference pass

Option 3: Supply Chain Technical Symposium

Pre-conference activities
From risk management to supply chain security, this workshop provides you with case studies showing how to improve your supply chain efficiency. Key areas of discussion include:
 
  • Compare and contrast real time track & trace methods
  • How packaging facilities and solutions can impact supply chain efficiency
  • The impact of emerging technologies
  • Understand cross-Asia regulations and how you can remain compliant
14:10
Conference pass

Panel discussion: Understanding the challenges Hong Kong, Malaysia, Indonesia, Thailand and Singapore have in providing orphan drugs to their rare disease patients

Orphan drug congress
  • Regulatory approval and market access policies in each of the countries
  • What are the predominant diseases in the country? What are the known rare disease indications in the country? 
  • Issues on rare disease awareness, affordability and political will
  • Are rare diseases and orphan drug being discussed at all? What does the government think of it and what could be a potential next step towards a Rare Disease Act?
  • What can patients, drug manufacturers and other stakeholders do to help?
15:30
Conference pass

Establishing long-term solutions to improve the diagnosis pathway

Orphan drug congress
  • Accessing the highest quality diagnostic testing for some lysosomal storage disorders
  • Pedigree Analysis Call to Action and genetic testing: raising awareness of the importance of a family history evaluation
  • Evaluating different screening methodologies to support early detection of rare diseases
  • Establishing patient registries to better understand rare disease and diagnosis pathway
15:50
Conference pass

Expanding newborn screening to include four more rare diseases: global updates

Orphan drug congress
  • Adding Homocystinuria, maple syrup urine disease, Glutaric aciduria type 1 and Isovaleric acidaemia to a list of rare diseases detected at birth
  • Practices on neonatal screening,
  • Identifying types of medical management and follow up
16:10
Conference pass

Panel discussion: Consolidating newborn screening efforts to detect rare diseases in the Asia-Pacific region

Orphan drug congress
  • Present status and future concerns of newborn and expanded newborn screening in Asia
  • Collaborating and cooperative networking to facilitate the development of sustainable newborn screening systems
  • Identify creative funding mechanisms such as inclusion in maternal/child health packages and health/social insurance

Create your personal agenda –check the favourite icon

09:10
Conference pass

The future of medicine and how it impacts patients, pharma, physicians and regulators.

Keynotes
In the digital age, with technology changing so rapidly, how can we make sure that we are prepared for the future? This exciting opening address for BioPharma Asia 2017 will explore the most exciting trends, ideas and technologies driving the future of our industry, including practical advice on how you can brace your business for the times ahead.
 
09:40
Conference pass

Blockchain meets Biopharma: How to prepare for the global data evolution

Keynotes
When you hear blockchain, you don’t necessarily think biopharmaceuticals. But the applications of blockchain can do so much more than digital currency. For example, it can help to increase the efficiency of the drug development process, by providing better security and transparency. It allows you to indelibly record medicinal and genomic data to combat counterfeit pharmaceutical production and protect intellectual property. That’s just a few applications. Join us as we uncover more and also consider some of the potential challenges that could be created, for example, around compliance and privacy.
 
10:10
Conference pass

Redesigning healthcare system with artificial intelligence

Keynotes
Some believe that artificial intelligence (AI) will lead to the end of human race, but there are also very clear benefits that AI could bring to the biopharma industry. Besides crunching data more efficiently and helping facilitate healing, AI can help in cutting clinical trial costs and time, thereby quickening the drug development process and getting much-needed drugs to market faster. Find out how AI can help companies to improve profit margins and deliver personalised treatments to patients in this exciting keynote session.
 
11:30
Conference pass

Moving from generics production to investing in innovative products: Is this the right approach in developing countries?

Asia Pharma Leadership Track
While IP laws are essential in promoting creativity and innovation, generics drugs are crucial to meet affordable healthcare demands in developing countries. While more countries are spending heavily to encourage the building of R&D centres, does it make sense for existing generics companies to shift towards producing innovative drugs? Join this case study to find out more.
 
11:30
Conference pass

Company presentation-Imugene

Biotech innovation
Eliminating gastric cancer in Asia with B cell peptide immunotherapy – clinical update
 
Dr Nick Ede, Chief Technology Officer, Imugene Ltd
11:30
Conference pass

Asia’s market access landscape: Understanding the perspectives of payers, healthcare policy makers, pharma and patients

Market Access
  • Exploring strategies to satisfy healthcare needs by working closely with pharma, policy makers and payers
  • Understanding key considerations and priorities from the payers’ perspective
  • Formulating an efficient communication channel for building a sustainable healthcare environment
Cyril Grandchamp-desraux, ASEAN Zone Head Rx and Singapore Country Chair, Sanofi
11:30
Conference pass

Key considerations in designing clinical trials protocols for pan-Asia clinical studies

Clinical trials
  • Where are the next clinical trial hotspots in Asia?
  • Exploring external R&D partnerships to accelerate new drugs to market
  • Discovering key preferred countries in conducting trials from pre-clinical, early phase to patient safety and consent
  • Strategies for navigating Asia’s fragmented regulatory landscape
11:30
Conference pass

Keeping up with the production demands of an evolving portfolio in Asia

Manufacturing
  • Understanding the challenges associated with the biomanufacturing of an evolving portfolio
  • Balancing flexibility, scalability and cost of manufacturing of emerging biological products
  • Case study on manufacturing of immuno-oncology products
11:30
Conference pass

Establishing coherent supply chain practices in Asia

Supply Chain
  • Promoting free trade movement to encourage trade and economic growth – where are we now and what’s next?
  • Encouraging the alignment of regulations and standards to ensure hassle free movement of goods and people
  • Overcoming IP, trade secret and safety regulation while opening borders
  • Investigating the possibility of achieving coherency in border regulation and movement of goods with the Trans-Pacific Partnership Agreement.
11:40
Conference pass

Company presentation-Novogen

Biotech innovation
11:50
Conference pass

Supporting R&D in developing markets: A private equity perspective

Asia Pharma Leadership Track
With a strong preference for cheaper healthcare alternatives, it’s not uncommon for them to select generic drugs as the treatment of choice. When a country’s priority lies in providing basic needs, it is only natural for there to be a much lesser focus on R&D from a financial perspective. In such a developing landscape, how can private equity play a role in promoting innovation and R&D? How do fund managers justify the risk and make their investment worthwhile? How can pharma and biotechs work more effectively with them to foster innovation?
 
Dr Judith Li, Partner, Lilly Asia Ventures
11:50
Conference pass

Company presentation

Biotech innovation
Mr Weon Kyoo You, R&D Head and Vice President, A.B.L. Bio
11:50
Conference pass

Balancing costs and benefits when partnering with academic CRO

Clinical trials
  • Exploring various partnership models available in conducting clinical trials in Asia
  • Discovering key considerations when selecting CROs- what should be expected and why?
  • Case study: Working with academic and commercial CRO for immuno-oncology clinical research in Asia
11:50
Conference pass

Integrating hybrid options in biomanufacturing: Economic and operational implications

Manufacturing
  • Discovering the best strategy for integrating disposable solutions in existing facilities
  • Realising the need for flexibility and scalability of hybrid manufacturing system in producing emerging therapeutic products
  • Practical advice for integrating hybrid systems in your manufacturing operations
Mr Junli Zhang, Chief Operating Officer and Senior Vice President, Shanghai Henlius Biotech Co Ltd
12:00
Conference pass

Company presentation

Biotech innovation
12:10
Conference pass

Improving accessibility of cancer drugs in developing countries

Asia Pharma Leadership Track
Let’s face it, newly marketed oncology drugs will always be expensive to recover costs. However, several big pharma players have started to loosen up patent protections to allow residents in less developed economies to enjoy more affordable treatment. While this bold approach is applauded by humanitarian organisations, the big question remains how to balance affordability and profitability of drugs and companies to sustain global operations.
 
12:10
Conference pass

Company presentation

Biotech innovation
12:10
Conference pass

Pricing strategies and key considerations for bringing drugs from red to blue ocean markets in Asia

Market Access
  • Risk assessment and management in post market drugs
  • Discover strategies for accessing this market, and navigating the fragmented regulatory framework in Asia
  • Opportunities for working with country regulators to harmonise general, locally-adaptable guidelines improving drug access for patients
12:10
Conference pass

Meeting the needs of patients: Practical advice for clinical developers planning pan-Asia trials

Clinical trials
  • Ensuring patient centricity of your clinical practices, through close communication with CROs, trial sites and partners
  • Building the optimal communication methods with patients, for example, setting up apps or dedicated call centres
  • Working with patient advocacy groups to better understand patient needs
Stephanie Liu, Senior GCQA Advisor, Global CQA, Lundbeck Singapore
12:10
Conference pass

Next generation processes: What model works the best in Asia?

Manufacturing
  • Compare and contrast the available full scale processing technologies, and discover what works the best for manufacturing next generation therapeutic products in Asia.
12:10
Conference pass

Handling challenges raised from parallel imports

Supply Chain
  • Understanding impact of grey market imports in drug pricing and motivation to innovate in Asia
  • Exploring various pricing strategies to overcome parallel import of genuine products
  • Exploring repackaging requirements for none authorised distributor prevent patient misinformation
12:20
Conference pass

Company presentation

Biotech innovation
Jeng Her, Chief Executive Officer, Ap Biosciences Inc
12:30
Conference pass

Will performance-based reimbursement be the future scheme in Asia?

Market Access
  • Discovering benefits of performance-based patient access schemes, as an alternative to current reimbursement plans in countries across Asia
  • Understanding the challenges in implementing risk sharing schemes in Asia
  • Identifying key practices required for long term viability of performance based drug reimbursement
  • Is a strategy like this even possible when multiple country regulators are involved?
12:30
Conference pass

Drawing parallels between EU and Chinese safety regulations

Clinical trials
  • Understanding safety requirements in clinical Phase 1 to 4 trials
  • Developing cross functional teams to streamline safety operations
  • Ensuring compliance and adherence to relevant regulations in EU and Asia
12:30
Conference pass

In-house manufacturing vs outsourcing: How to balance benefits and costs when selecting CMO in Asia?

Manufacturing
Hear first-hand on key considerations when selecting CMOs for bioproduction in Asia
12:30
Conference pass

Emerging compliance supply chain requirements in Asia

Supply Chain
  • Establishing collaborative, enterprise wide process for communicating compliance requirements with suppliers
  • Ensuring clear assignment of compliance execution ownership for compliance adherence to local regulations
  • Using constant engagement and linkage of individuals throughout an organization to prevent delay and potential loss of sales and product obsolescence
12:30
Conference pass

Biomolecular manufacturing “on-the-go” for developing, inaccessible countries with freeze drying cellular components

Asia Pharma Leadership Track
With freeze drying techniques, it may be possible to generate essential proteins by simply adding water. This may potentially overcome drug accessibility problem in poorer countries lacking necessary cold chain infrastructure
14:20
Conference pass

Choosing which –omics to invest in and how to do it in Asia

Asia Pharma Leadership Track
Discover the best strategy to de-risk our investment and evaluate the right portfolio to invest, being genomics, proteomics or metabolomics.
 
14:20
Conference pass

Company presentation

Biotech innovation
Hui (David) Shao, Chief Financial Officer, Yisheng Biopharma
14:20
Conference pass

Exploring country-specific market access strategies

Market Access
  • Besides pricing and reimbursement, what are the other factors in consideration when accessing a new market in Asia?
  • Understanding the role of patient groups and the importance of patient-centric approaches in defining your access strategy
  • Overcoming regulatory hurdles: How can we handle the fragmented regulatory structures?
  • Licensing by reciprocity in Asia: Is it even possible?
14:20
Conference pass

Overcoming registration and submission challenges in pan-Asia clinical studies

Clinical trials
  • What has changed since last year’s meeting?
  • How can RA representatives be more effective in navigating through the fragmented SEA market?
  • Exploring the possibility of using an adaptive regulatory submission system, customised from established markets
  • Established vs. emerging markets in Asia
14:20
Conference pass

Understanding regulatory restrictions in implementing new biomanufacturing processes

Manufacturing
  • Understanding the regulatory requirements for modifying bioproduction processes in their respective countries
  • Discussing strategies for speeding up approval procedures to upgrade bioprocesses
  • Is it worth the time and resources to upgrade existing manufacturing processing to continuous systems?
14:20
Conference pass

Panel: Innovative supply chain solutions to improve agility and efficiency

Supply Chain
  • Formulating strategies to ensure optimal process flow
  • Exploring various options to satisfy segmentation requirements with variable volumes and packaging needs
  • Using late stage customisation to overcome country specific regulations and requirements 
  • Overcoming existing infrastructure limitations to fully utilise the potential of 2D barcoding in track and trace
14:40
Conference pass

Impact of Singapore’s S$13billion R&D expenditure commitment on SEA biotech industry

Asia Pharma Leadership Track
R&D is the key to innovation and requires heavy investment of both time and resources. With the shift in economic focus from the traditionally viewed blue chip industries, the biotech industry is an attractive option for global investors. Discover how Singapore’s commitment to R&D is building investor confidence in SEA’s biotech industry, and enabling it to compete with neighbouring strongholds.
 
14:40
Conference pass

Process development preparation for effective technology transfer and operation

Manufacturing
  • From R&D to manufacturing operations, what are the considerations required to ensure smooth transfer?
  • Evaluating critical aspects to evaluate to ensure event free manufacturing
  • Discovering the importance of cross function communication to promote successful routine bioproduction
Dr Jacob Jensen, Senior Manager, Technology Transfer, Biogen
15:00
Conference pass

PANEL: Key considerations when considering IPO vs Acquisitions

Asia Pharma Leadership Track
It may be overly simplistic, but generally speaking, there are 2 ways in which biotech companies grow their business. Going public helps to gain more capital and investments for further developments, while keeping more control of the direction of growth of the company. On the other hand, acquisition by one an industry stalwart can also be a very attractive option, as it opens up access to resources and additional expertise. We explore what’s right for your business.
 
15:00
Conference pass

Promoting regulatory innovation in Singapore and the rest of Asia

Clinical trials
  • Understanding the need for creating a  simplified, innovative regulatory framework to support the exponentially-growing number of trials in Asia
  • Strategies for improving regulatory expertise and cross-nation support for promoting regulatory policy innovation
  • Discussing methods to remove or reduce regulatory complexity, and minimise the impact of regulatory diversity, to ensure timely access to safe, high quality therapeutic products
15:00
Conference pass

From clone to pilot plant scale up: Case study of developing a CHO cell culture platform for antibody production from OPEX perspective

Manufacturing
This presentation will explore steps in upscaling antibody production from clone to manufacturing scale, including process development, tech transfer and quality measurements
15:00
Conference pass

Innovate cargo monitoring and tracking for pharmaceutical products with IoT

Supply Chain
  • Understanding the infrastructure requirements for using IoT for supply chain in Asia
  • Balancing cost and benefits in using IoT to ensure quality of products delivered
  • Case study in Asia: Strides
15:20
Conference pass

India’s latest biosimilars guidelines: Opportunities and threats to generics and innovation driven pharma

Clinical trials
  • Understanding key concerns and considerations when working on biosimilars products in India
  • How do pharma companies leverage on India’s regulatory landscape to launch biosimilars products?
  • Should biosimilar industry be worried over AbbVie’s IPR success case vs Amgen in the US and most recently India’s latest biosimilars guidelines?
15:20
Conference pass

Identifying matrices to improve human performance in Asia biopharmaceutical plant

Manufacturing
  • Identification and prevention of true human error events in manufacturing plants
  • Improving human performance through operational excellence
  • Case study in Singapore
Mr Christian D. Cater, Associate Director, Business Excellence,, Roche
15:20
Conference pass

Streamlining supply chain with Big Data

Supply Chain
  • Discover how big data can help you handle your supply chain more easily in Asia
  • Understanding the benefits of using cloud, data and analytics to drive operational efficiencies
  • Overcoming challenges in real time transmission of data into cloud storage
16:20
Conference pass

Table 1 Countries specific strategies in overcoming challenging green field regulatory landscape

Keynotes
16:20
Conference pass

Table 3 Globalizing Clinical Trial Operations – Asia’s emerging leadership role

Keynotes
Mr Robert Bruno, Director of Clinical Operations, Abbvie Japan
16:20
Conference pass

Table 4 Talent management and communication strategies in pharma landscape

Keynotes
Maggie Sy, Director - Asia Sourcing And Procurement, Mead Johnson & Company
16:20
Conference pass

Table 6 Strategies to overcome production challenges when starting new manufacturing project in Asia

Keynotes
16:21
Conference pass
16:21
Conference pass

Table 10 Building sustainable innovation ecosystem in Asia

Keynotes
17:00
Conference pass

Overcoming credibility issues in Asia clinical trials and manufacturing processes

Keynotes
With two third of world’s population residing in Asia, it is unsurprising that Asia is the next market where biopharma are investing to grow. However, plagued with scandals and quality issues, many small to mid-size overseas companies are hesitating to enter the value chain here. In this presentation, we explore how stakeholders in Asia can work together to produce higher quality results and products to regain global confidence in the region.
 
17:20
Conference pass

Keeping patient centricity as an intrinsic goal in Asia pharmaceutical companies

Keynotes
Everyone wants to be a part of the lucrative Asia pharma market, but how do we make sure that our company is innovative enough to keep out competitors, while keeping patients’ interest as the ultimate objective to deliver health and healing? In this session, we explore how you can use a patient centricity approach to differentiate your business operation from your competitors.
 

Create your personal agenda –check the favourite icon

09:10
Conference pass

From ideas to international success: A real breakthrough story brought to you by an Asian biotech company

Keynotes
Starting from nothing to million dollar success, this biotech company currently employs thousands to benefit the healthcare industry. Hear from true blue biotech company in Asia on their success story in building the reach of their companies from domestic to international market
 
Interviewee: Dr Carl Firth, Chief Executive Officer, ASLAN Pharmaceuticals
Interviewer: Ed Lane, Senior Editor, Fierce Pharma Asia
09:30
Conference pass

Keynote Panel: Big pharma perspective in driving Asia biopharma innovation

Keynotes
With the highest amount of resources which can be invested into operation, big pharma companies are in the best position to lead the industry direction. When making a key decision, it is important to understand the impact in organisation and industry wide. How can big pharma avoid being “too-big-to-fail” and lead the industry to be more innovative? 
 
10:10
Conference pass

Strategies in providing affordable healthcare in developing countries

Keynotes
Developing countries are facing enormous challenges when it comes to dedicating natural funds and resources. In the dilemma between investing on more economy boasting industries, and providing better healthcare infrastructure and facilities for the people, the former often get more attention to promote overall growth of the country. In Asia, many countries depend on out-of-pocket to fund healthcare policies, the big question is, how can stakeholders work together in providing accessible and affordable healthcare in limited funding by the government and people to afford these services?
 
11:15
Conference pass

Change management to adopt readily available technology in pharma landscape

Asia Pharma Leadership Track
Change is the unavoidable part of innovation; you need to keep up with the pace of industry. Discover how pharma managers can establish open communication strategy and clearly communicating the purposes and meaning when implementing changes.
 
11:15
Conference pass

Company presentation-Immunwork

Biotech innovation
Dr Tse Wen Chang, Chairman and Founder, Immunwork Inc.
11:15
Conference pass

Medical led stakeholder engagement: How can drug providers better interact with patients and healthcare professionals in Asia?

Medical Affairs
  • How can pharma providers better engage patients and investigators by setting aside investigator led funding, education grant and trial grant bonds for quality studies?
  • Discovering strategies in making patients the priority in medical communication
  • Exploring options to provide support, sponsorship and resources to patient groups and care givers
11:15
Conference pass

Digitalising healthcare practices in clinical operations

Clinical trials
  • Using cloud, analytics, and electronic source to fast track studies and potentially even approval processes
  • Redefining SOP in clinical operations to integrate technology into practices
  • Discovering strategic plans to train staff in moving towards digitalised practices
11:15
Conference pass

Using QbD as the core design principle in continuous processing

Manufacturing
  • Overcoming regulatory uncertainties in using continuous processing
  • Does continuous manufacturing really help to reduce drug development and commercialisation costs?
  • Navigating regulatory guidelines to ensure compliance
11:25
Conference pass

Company presentation- PharmAbcine

Biotech innovation
11:35
Conference pass

Big data: Is it a hype or a hope for upcoming reality?

Asia Pharma Leadership Track
Everyone in the world is excited about big data. With super computer power to analyse, capture, search, share and store information, its huge potential can be translated into drug discovery, clinical development, patient recruitment, and even post clinical marketing and sales processes of pharma companies. The big question remains: Is this just a hype by idealistic techies and too good to be true, or is this really happening in the industry?
 
11:35
Conference pass

Company presentation- BRIM Biotech

Biotech innovation
Lilly Zhang, Senior Director, R&D and Business Development, BRIM Biotechnology
11:35
Conference pass

Payer, policy maker and provider engagement

Medical Affairs
  • Exploring key relationship building strategy in working with payers and policy makers
  • Understanding the concerns and priorities of stakeholders when building relationships with the national guideline committees
  • Country case studies: How to successfully engage stakeholders for medical studies and drug reimbursement conversations
Manish Garg, Medical Director, MSD Pharmaceuticals
11:35
Conference pass

Enabling remote monitoring in clinical studies

Clinical trials
  • Discussing possible benefits in using advanced sensing technology for off-site patient monitoring
  • Understanding technology available in providing personalised care for patients
  • Overcoming challenges to widely implement remote monitoring in Asian clinical studies
11:35
Conference pass

Identifying production control attributes in upgrading batch to continuous bioproduction

Manufacturing
  • Understanding the best design principles to ensure a consistent flow of products
  • Integrating robust process controls and monitoring systems in continuous design
  • Adopting analytical technologies and mathematical modelling to facilitate the adoption of continuous processing
11:45
Conference pass

Company presentation-Saksin Life Sciences

Biotech innovation
11:55
Conference pass

CRISPR and how it disrupts pharma industry

Asia Pharma Leadership Track
CRISPR has succeeded CPR as the next genetic breakthrough in the biomedical R&D world. Besides great hope and greater expectations to cure incurable diseases, there are worries about humans “playing god” to create supreme “super-organism” against nature’s order. How do pharma leaders establish compliance clause and prevent technology misuse for the better of humanity?
 
11:55
Conference pass

The patient advocate perspective: Working better with pharma and key stakeholders to provide better patient care

Medical Affairs
  • Exploring various working strategies in pre-clinical execution phase collaboration to promote disease awareness
  • Working with patient groups to deliver better treatment outcomes, i.e. creating patient registry for drug trial recruitment and outreach
  • Understanding potential collaboration and partnership opportunities between pharma, patient advocacy groups and government units
11:55
Conference pass

Integrating emerging technology into an effective adverse reporting process

Clinical trials
  • Understanding how improving current legislation helps to improve medical communication with patients and physicians
  • Exploring the benefits in keeping up to cloud technology and social media
  • Discovering how pharma companies can leverage on latest technology to reduce drug misinformation
11:55
Conference pass

Drawing the parallel between small and large molecules: What can we learn from our industry peers?

Manufacturing
  • Understanding the requirements of continuous bioprocessing
  • What can biologics manufacturing learn from small molecules and formulations team to continuously process biological products
12:15
Conference pass

From pre- to post- launch: Improving the role of medical affairs in product life cycle management

Medical Affairs
  • Understanding the different roles of medical affairs personnel in reimbursed market
  • Exploring how medical affairs personnel help in pharma marketing
  • From design, execution and supporting investigator initiated studies, how can medical affairs better utilise the available clinical outcomes to convince stakeholders in reimbursement decisions? 
Dr Pranab Kalita, Medical Director - Medical Affairs - Lundbeck SEA, Lundbeck Singapore
12:15
Conference pass

Innovation in action: Using remote sensing and IoT for stroke patient monitoring

Clinical trials
  • Using IoT for real time patient monitoring
  • Discussing infrastructure limitation and potential solutions in overcoming these challenges
  • Sharing case studies on using remote sensing for patient monitoring off-sites
12:15
Conference pass

Continuous processing in Asia: A case study

Manufacturing
  • What are the added benefits in adopting continuous processing?
  • Compared to conventional biomanufacturing, what are the additional precautions required for successful implementation?
  • Moving forward, what’s next after continuous processing?
13:50
Conference pass

Changing landscape in First-in-Human studies, in the era targeted drugs and immunotherapy

Asia Pharma Leadership Track
The existing cancer therapy methods are often harmful and detrimental to the health of patients. While targeted therapy is becoming the hot discussion topic within the industry, research process is still too expensive and lengthy to quickly bring drugs from bench to beside. In this presentation, changing landscape of therapy methods will be explored along with the prediction of next generation drugs and its study methods to help speeding up the drug discovery process.
 
13:50
Conference pass

Company presentation Orally-delivered antiviral protein for Dengue and Zika

Biotech innovation
Mr Eng Huan Ung, Chief Technology Officer, BioValence Sdn Bhd
13:50
Conference pass

Using evidence-based discussions to build pharma reputation and brand recognition

Medical Affairs
  • Discovering strategies to further develop and translate worldwide evidence base for local applications
  • Improving uniformity and consistency in local investigator led studies
  • Navigating policy intervention in scientific, evidence based decision making processes
Dr Viraj Rajadhyaksha, Medical Director for Malaysia, Singapore and Brunei, AstraZeneca
13:50
Conference pass

Cost and considerations in selecting CRO for end-to-end operations and supply

Clinical trials
  • Exploring the availability of high quality, cost effective CRO services in Asia
  • Working with CROs to implement best practices in clinical supply
  • Discovering strategies to innovate clinical supply practices
13:50
Conference pass

QbD and beyond- where are we now in Asia?

Manufacturing
  • In some countries, QbD has been listed as one of the requirements in the submission for approval. What is the status in Asia and how can manufacturers continuously innovate to improve production cost and quality?
  • Identifying critical process parameters and critical quality attributes to ensure robust technology transfer
14:10
Conference pass

Clinical safety studies and key considerations in biosimilars drugs

Medical Affairs
  • Discovering key parameters to be considered when studying safety of biosimilars in clinical phase
  • Originator vs biosimilars: what needs to be considered in pharmacovigilance studies
  • Understanding how data collected helps in supporting market access mission of medical affairs when working with biosimilars drug
S.D Sinha, Associate Vice President & Head (Global)-Clinical Development, Medical Affairs & Pharmacovigilance, Hetero Drugs Ltd
14:10
Conference pass

Driving patient centricity to optimize clinical supply

Clinical trials
  • Understanding the evolution of the clinical supply model
  • Need a new approach: internal pressures to drive efficiency, quality and value while reducing risk
  • Case Study:  a fundamentally different approach to other clinical supply models
14:10
Conference pass

Ensuring excellent production quality of emerging therapeutic products

Manufacturing
  • Discover GMP and cGMP guidelines in manufacturing of novel biologics, i.e. biosimilars, in Asia
  • Vendor selection and management: How do we measure the quality success of our vendors?
  • China case study
Amy Que, Innovent Biologics Co., Ltd.
14:30
Conference pass

Strategy of sequencing the whole genome and its impact of next generation medicine

Asia Pharma Leadership Track
Targeted therapy is an essential part of immuno-oncology. With the help of biomarkers, immuno-oncology helps better targeting of drugs to minimise toxicity and improve efficacy. What’s the key strategy in sequencing whole genome from a clinical perspective and how does it help to bring closer to the future of personalised medicine?
 
Jurgen Eils, Group Leader, German Cancer Research Center (DKFZ)
14:30
Conference pass

Adopting HEOR to balance short-term goals and long-term market access goals

Medical Affairs
  • Using HEOR to convince healthcare authorities on drug functions and value
  • Key strategies for presenting collected medical research data and demonstrate drugs value
  • Discover the importance of HEOR in countries without a reimbursement framework
Dominique Milea, Director, Health Economics & Epidemiology Asia, Lundbeck
14:30
Conference pass

Innovative supply chain strategies to improve agility and efficiency

Clinical trials
  • Formulating strategies to ensure optimal process flow
  • Exploring various options to satisfy segmentation requirements with variable volumes and packaging needs
  • Using late stage customisation to overcome country specific regulations and requirements 
  • Overcoming existing infrastructure limitations to fully utilise the potential of 2D barcoding in track and trace
Patrik Jonasson, Director, Public Policy Asia Pacific, G.S.1 Malaysia
14:30
Conference pass

Quality assurance and control requirements for cell therapy products

Manufacturing
  • From facilities to equipment and material, how do manufacturers make sure that cell therapy products are manufactured in well-controlled manner?
  • Exploring how a risk-based approach helps in biomanufacturing QA measurements
  • Deriving quality measurements to ensure compliance in upscaling from clinical stage
14:50
Conference pass

Innovation and implementation of precision medicine

Asia Pharma Leadership Track
Precision medicine is the next step forward towards personalised medicine in the future. With the help of biomarkers and emerging technologies, it is very possible that one will soon be able to diagnose patients and cater to their healthcare needs with minimum risk at an affordable rate. But that’s easy to plan and hard to implement. Hear how precision medicine companies aim to be the future of medicine and the impact of precision medicine on the human population.
 
14:50
Conference pass

Key performance indicators in measuring the success of HEOR

Medical Affairs
  • How can companies prioritise HEOR spending to best impact payers’ pricing decisions?
  • Balancing financial and manpower investments to maximise the output of resources invested
  • Promoting proper data analysis throughout the drug development process to ensure accurate communication with stakeholders
14:50
Conference pass

Optimising product and process parameters with Design of Experiment (DoE)

Manufacturing
  • Using DoE as a compliment to QbD
  • Developing critical quality attributes in process monitoring and validation
  • Modelling approaches to gain full benefit of DoE in satisfying quality design and development activities
14:50
Conference pass

Preventing GI antibiotic resistance in Asia

Asia Pharma Leadership Track
Antimicrobial resistance (AMR) is an increasing problem in developed countries and will affect Asia if not handled properly. This session discuss the potential solution for global AMR problem.
 
15:40
Conference pass

Treating lifestyle diseases in Asia

Asia Pharma Leadership Track
Better overall economies in Asia have grown the number of middle income inhabitants and families within the region. From a big pharma perspective, this is a good opportunity to enter the market to provide treatments for lifestyle-related diseases which are common in developing and developed markets. As a pharma leader making such a decision, how do you gauge the dollar potential and make APAC your next sales target?
 
15:40
Conference pass

Company presentation

Biotech innovation
Cathy Lui, Co Founder, OPER Technology Limited
15:40
Conference pass

Establishing the medical affairs role as a cornerstone to build trust in pharmaceutical industry

Medical Affairs
  • Discovering strategies to ensure medical compliance within institution
  • Exploring ways in building strong, multi-faceted medical affairs organisation to navigate global healthcare landscape
  • Case study
15:40
Conference pass

Balancing cost and efficiency in performing quality clinical operations

Clinical trials
  • Staffing and training strategies to ensure quality clinical operations
  • Exploring possibilities in widely implementing risk-based monitoring
  • Offsetting the limitation of on-site monitoring with risk based monitoring
15:40
Conference pass

Chemical stability of protein drugs - Degradation mechanisms and strategies to improve product stability in biomanufacturing

Manufacturing
  • Developing high stability indicating assays
  • Coping with the latest configurations, reagents and alternatives in method validation and performance
  • Exploring automation as a method for streamlining QC processes and maintaining uniformity of analytical processes
Min Li, Vice President, Analytical Operations, Zhejiang Huahai Pharmaceutical Co Ltd
16:00
Conference pass

Cultivating patient centricity in the evolving role of medical affairs

Medical Affairs
  • Strategies for implementing patient centricity frameworks within India pharma companies
  • Crafting patient education and engagement programs in South Asia
  • Emphasizing data, quality and sincerity as integral core values in medical practices
Hema Bajaj, Head of Clinical Quality and Medical Compliance Affiliate Quality Officer, Sanofi Pasteur
16:00
Conference pass

Conducting quality clinical trials in China, a case study

Clinical trials
The Chinese government has recently reformed its healthcare structure to improve quality of clinical trials and manufacturing. Find out more about the status quo of clinical operations in China and how global companies can help in ensuring quality operation by strictly enforcing GCP and other SOP in their respective team.
16:00
Conference pass

Biocomparability and stability studies in biosimilar production

Manufacturing
  • Key characterisation techniques to ensure biosimilar functionality
  • Discussing strategies to maintain product quality in upscaling biosimilar
  • Exploring key assays techniques and development for biosimilar testing
Venkat Yeturu, Director, Biologics, Dr Reddys Laboratories
16:05
Conference pass

Minimising the number of cases of “preventable” liver cancers in Asia by more affordable vaccination

Asia Pharma Leadership Track
It takes an average of 20-30 years for chronic Hepatitis B to progress into cancer, thus vaccination can be the solution to minimise mortality rate of individuals in Asia due to liver cancer. Perhaps the biggest challenge for this initiative is discover strategies in making vaccines more affordable in under-developing and developing countries.
 
16:20
Conference pass

Competency and compliance training of medical staff

Medical Affairs
  • Establishing guidelines and structures to promote cross functional team working and communication
  • Ensuring staff to adhere to required SOPs and comply with regulations
  • Strategies in training medical affairs staff to adhere to consistent, high quality standards
16:20
Conference pass

How can big pharma lead GCP implementation to promote quality clinical research in India?

Clinical trials
Clinical trials in India have been plagued with scandals due to lack of compliance and ambiguous guidelines. While the CDSCO is renewing its policy to promote quality trials in the country, local companies need to learn from their overseas counterparts to regain international confidence in the market. Find out how big pharma in India can help in leading GCP within the country.
Dr Joseph Marialouis, Associate Director-Clinical Operations, Lupin
16:20
Conference pass

Enhancing purification and analytical techniques in bispecific biologics production

Manufacturing
  • Discussing the potential application of using 2D liquid chromatography to characterise therapeutic proteins
  • Developing critical attributes for deciding on the analytical techniques to be used in bioproduction
  • Case study: Bispecific antibody production
16:40
Conference pass

Innovate, discover and commercialise treatments for heart failure

Asia Pharma Leadership Track
Heart failure affects a younger population as compared to the past and is currently a major burden in East Asia. With high associated risk of mortality and morbidity, research in this category of disease can pose a great opportunity for pharma and biotech companies in both dollars and humanitarian sense.
 
16:40
Conference pass

Encouraging investigator-led studies in Asia

Medical Affairs

·         Understanding how investigator led studies encourage drug access and reduce drug price in countries

·         Providing easier access to drugs to encourage investigator led studies

·         Establishing better reporting system by taking account of patient’s opinions

Dr Abhishek Bhagat, Medical Director, Asia, Abbvie Ptd Ltd
16:40
Conference pass

Is Vietnam the next China in Asia?

Clinical trials
With the increasing labour cost and lack of IP protection in China, companies are shifting their focus to its neighbour: Vietnam. Home to over 80 million population with one of the least advanced healthcare infrastructure in Asia, Vietnam poses one of the highest potential in the eye of industry. Find out how pharma companies venture and overcome barriers in conducting trials in Vietnam from this session.
16:40
Conference pass

Host cell protein (HCP) characterisation and mass spectrometry strategies

Manufacturing
  • Adding mass spectrometry as part of the host cell protein workflow
  • Analytical strategies in HCP identification and purification process
  • Developing quantitative MS/MS methods to determine HCP levels